Nanoencapsulation of tacrolimus in lipid-core nanocapsules showed similar immunosuppressive activity after oral and intraperitoneal administrations

Journal of Biomedical Nanotechnology

Volumn 10, Issue 8, 2014, Pages 1599-1609

  Friedrich, R B ^a   Dimer, F A ^a   Guterres, S S ^a   Beck, R C R ^a   Pohlmann, A R ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Immunosuppressive activity; Lipid core nanocapsules; Oral administration; Polymeric nanoparticles; Tacrolimus

Indexed keywords

BIOCHEMISTRY; DRUG DOSAGE; ENCAPSULATION; PHARMACODYNAMICS;

ENCAPSULATION EFFICIENCY; GASTROINTESTINAL DISORDERS; INTRAPERITONEAL ADMINISTRATION; LIPID-CORE NANOCAPSULES; ORAL ADMINISTRATION; POLYMERIC NANOPARTICLES; TACROLIMUS; TRANSPLANT REJECTION;

NANOCAPSULES;

LIPID CORE NANOCAPSULE; NANOCAPSULE; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DIFFUSION; DRUG EFFICACY; DRUG SOLUTION; DRUG TRANSPORT; ELECTROPHORETIC MOBILITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LASER DIFFRACTION; LEUKOCYTE DIFFERENTIAL COUNT; LIGHT SCATTERING; LIPOSOMAL DELIVERY; LYMPHOCYTE; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; SUSTAINED DRUG RELEASE; WEIGHT GAIN; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, PARENTERAL; LIPIDS; LYMPHOCYTES; MALE; MICE; NANOCAPSULES; TACROLIMUS;

EID: 84899678943     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1842     Document Type: Article

References (64)

1. T. Kino, H. Hatanaka, M. Hashimoto, M. Nishiyama, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka, FK-506, a novel immunosuppressant isolated from a streptomyces, I. Fermentation, isolation, and physico-chemical and biological characteristics. J. Antibiot. 40, 1249 (1987).
2. A. L. Taylor, C. J. E. Watson, and J. A. Bradley, Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol. 56, 23 (2005).
3. H. Nakagawa, Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: Review of randomised, double-blind clinical studies conducted in Japan. Clin. Drug Invest. 26, 235 (2006).
4. A. E. Xu, D. M. Zhang, X. D. Wei, B. Huang, and L. J. Lu, Efficacy, and safety of tarcrolimus cream 0.1% in the treatment of vitiligo. Int. J. Dermatol. 48, 86 (2009).
5. S. Kawai, H. Hashimoto, H. Kondo, T. Murayama, T. Kiuchi, and T. Abe, Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J. Rheumatol. 33, 2153 (2006).
6. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315, 196 (2005).
7. Y. Meissner, Y. Pellequer, and A. Lamprecht, Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery. Int. J. Pharm. 316, 138 (2006).
8. S. Heidt, D. L. Roelen, C. Eijsink, M. Eikmans, C. van Kooten, F. H. Claas, and A. Mulder, Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin. Exp. Immunol. 159, 199 (2010).
9. M. H. Kapturczak, H. U. Meier-Kriesche, and B. Kaplan, Pharmacology of calcineurin antagonists. Transplant. Proc. 36, S25-S32 (2004).
10. N. A. Undre, Pharmacokinetics of tacrolimus based combination therapies. Nephrol., Dial., Transplant. 18, i12 (2003).
11. H. Tatetsu, N. Asou, M. Nakamura, Y. Koh, T. Tajiri, F. Matsuno, K. Horikawa, Y. Yonemura, and H. Mitsuya, Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine. Rinsho Ketsueki. 44, 471 (2003).
12. Y. Chung and H. Cho, Preparation of highly water soluble tacrolimus derivatives: Poly(ethylene glycol) esters as potential prodrugs. Arch. Pharm. Res. 27, 878 (2004).
13. V. Borhade, H. Nair, and D. Hegde, Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS Pharm. Sci. Tech. 9, 13 (2008).
14. A. S. B. Goebel, R. H. H. Neubert, and J. Wohlrab, Dermal targeting of tacrolimus using colloidal carrier systems. Int. J. Pharm. 404, 159 (2011).
15. V. B. Borhade, H. A. Nair, and D. D. Hegde, Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev. Ind. Pharm. 35, 619 (2009).
16. K. Yamashita, T. Nakate, K. Okimoto, A. Ohike, Y. Tokunaga, R. Ibuki, K. Higaki, and T. Kimura, Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int. J. Pharm. 267, 79 (2003).
17. Y.-J. Park, D.-S. Ryu, D. Li, Q. Quan, D. Oh, J. Kim, Y. Seo, Y.-I. Lee, C. Yong, J. Woo, and H.-G. Choi, Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch. Pharm. Res. 32, 893 (2009).
18. M.-J. Lee, R. M. Straubinger, and W. J. Jusko, Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. Pharm. Res. 12, 1055 (1995).
19. M. Erdogan, J. R. Wright, and V. C. McAlister, Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: Experimental studies in a murine model. Br. J. Dermatol. 146, 964 (2002).
20. A. Y. Alemdar, K. A. Baker, D. Sadi, V. C. McAlister, and I. Mendez, Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats. Exp. Neurol. 172, 416 (2001).
21. O. Canadas, R. Guerrero, R. Garcia-Canero, G. Orellana, M. Menendez, and C. Casals, Characterization of liposomal tacrolimus in lung surfactant-like phospholipids and evaluation of its immunosuppressive activity. Biochemistry (Mosc.) 43, 9926 (2004).
22. S. M. Ali, A. Ahmad, S. Sheikh, M. U. Ahmad, R. C. Rane, P. Kale, M. Paithankar, D. Saptarishi, A. Sehgal, K. Maheshwari, and I. Ahmad, Polyoxyl 60 hydrogenated castor oil free nanosomal formulation of immunosuppressant tacrolimus: Pharmacokinetics, safety, and tolerability in rodents and humans. Int. Immunopharmacol. 10, 325 (2010).
23. S. Gao, J. Sun, D. Fu, H. Zhao, M. Lan, and F. Gao, Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β- cyclodextrin inclusion complex-loaded albumin nanoparticles. Int. J. Pharm. 427, 410 (2012).
24. H. Arimoa, K. Yunomae, F. Hirayama, and K. Uekama, Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 297, 547 (2001).
25. Y. Wang, C. Wang, S. Fu, Q. Liu, D. Dou, H. Lv, M. Fan, G. Guo, F. Luo, and Z. Qian, Preparation of tacrolimus loaded micelles based on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone). Int. J. Pharm. 407, 184 (2011).
26. A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima, Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. Eur. J. Pharm. Biopharm. 58, 37 (2004).
27. A. Lamprecht, H. Yamamoto, N. Ubrich, H. Takeuchi, P. Maincent, and Y. Kawashima, FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression. Pharm. Res. 22, 193 (2005).
28. T. Nassar, A. Rom, A. Nyska, and S. Benita, Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J. Controlled Release 133, 77 (2009).
29. P. Sinswat, K. A. Overhoff, J. T. McConville, K. P. Johnston, and R. O. Williams, Nebulization of nanoparticulate amorphous or crystalline tacrolimus - Single-dose pharmacokinetics study in mice. Eur. J. Pharm. Biopharm. 69, 1057 (2008).
30. T. Nassar, A. Rom, A. Nyska, and S. Benita, A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs. Pharm. Res. 25, 2019 (2008).
31. S.-B. Shin, H.-Y. Cho, D.-D. Kim, H.-G. Choi, and Y.-B. Lee, Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur. J. Pharm. Biopharm. 74, 164 (2010).
32. K. K. Singh and P. Pople, Safer than safe: Lipid nanoparticulate encapsulation of tacrolimus with enhanced targeting and improved safety for atopic dermatitis. J. Biomed. Nanotechnol. 7, 40 (2011).
33. P. Couvreur, G. Barratt, E. Fattal, P. Legrand, and C. Vauthier, Nanocapsule technology: A review. Crit. Rev. Ther. Drug Carrier Syst. 19, 99 (2002).
34. R. B. Friedrich, M. C. Fontana, R. C. R. Beck, A. R. Pohlmann, and S. S. Guterres, Development and physicochemical characterization of dexamethasone-loaded polymeric nanocapsule suspensions. Quim. Nova 31, 1131 (2008).
35. E. Jager, C. G. Venturini, F. S. Poletto, L. M. Colome, J. P. Pohlmann, A. Bernardi, A. M. Battastini, S. S. Guterres, and A. R. Pohlmann, Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed. Nanotechnol. 5, 130 (2009).
36. C. G. Venturini, E. Jäger, C. P. Oliveira, A. Bernardi, A. M. O. Battastini, S. S. Guterres, and A. R. Pohlmann, Formulation of lipid core nanocapsules. Colloids Surf., A 375, 200 (2011).
37. D. S. Jornada, L. A. Fiel, K. Bueno, J. F. Gerent, C. L. Petzhold, R. C. R. Beck, S. S. Guterres, and A. R. Pohlmann, Lipid-core nanocapsules: mechanism of self-assembly, control of size and loading capacity. Soft Matter 8, 6646 (2012).
38. A. R. Pohlmann, F. N. Fonseca, K. Paese, C. B. Detoni, K. Coradini, R. C. Beck, and S. S. Guterres, Poly(ε-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin. Drug Deliv. 10, 623 (2013).
39. M. C. Fontana, K. Coradini, S. S. Guterres, A. R. Pohlmann, and R. C. Beck, Nanoencapsulation as a way to control the release and to increase the photostability of clobetasol propionate: Influence of the nanostructured system. J. Biomed. Nanotechnol. 5, 254 (2009).
40. R. L. Frozza, A. Bernardi, K. Paese, J. B. Hoppe, T. da Silva, A. M. Battastini, A. R. Pohlmann, S. S. Guterres, and C. Salbego, Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 6, 694 (2010).
41. R. P. Bulcão, F. A. d. Freitas, C. G. Venturini, E. Dallegrave, J. Durgante, G. Göethel, C. T. S. Cerski, P. Zielinsky, A. R. Pohlmann, S. S. Guterres, and S. C. Garcia, Subchronic toxicity evaluation of poly(epsilon-caprolactone) lipid-core nanocapsules in rats. Toxicol. Sci. 132, 162 (2012).
42. A. Bernardi, A. C. Zilberstein, E. Jager, M. M. Campos, F. B. Morrone, J. B. Calixto, A. R. Pohlmann, S. S. Guterres, and A. M. Battastini, Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br. J. Pharmacol. 158, 1104 (2009).
43. A. Bernardi, R. L. Frozza, A. P. Horn, M. M. Campos, J. B. Calixto, C. Salbego, A. R. Pohlmann, S. S. Guterres, and A. M. Battastini, Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of neuroinflammation. Neurochem. Int. 57, 629 (2010).
44. F. Figueiro, A. Bernardi, R. L. Frozza, T. Terroso, A. Zanotto-Filho, E. H. Jandrey, J. C. Moreira, C. G. Salbego, M. I. Edelweiss, A. R. Pohlmann, S. S. Guterres, and A. M. Battastini, Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth. J. Biomed. Nanotechnol. 9, 516 (2013).
45. A. Zanotto-Filho, K. Coradini, E. Braganhol, R. Schröder, C. M. de Oliveira, A. Simões-Pires, A. M. O. Battastini, A. R. Pohlmann, S. S. Guterres, C. M. Forcelini, R. C. R. Beck, and J. C. F. Moreira, Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur. J. Pharm. Biopharm. 83, 156 (2013).
46. V. Filipe, A. Hawe, and W. Jiskoot, Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27, 796 (2010).
47. O. Mengual, G. Meunier, I. Cayré, K. Puech, and P. Snabre, TURBISCAN MA 2000: Multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta 50, 445 (1999).
48. P. Costa and J. M. S. Lobo, Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13, 123 (2001).
49. C. C. Muller-Goymann, Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur. J. Pharm. Biopharm. 58, 343 (2004).
50. F. Lince, D. L. Marchisio, and A. A. Barresi, Strategies to control the particle size distribution of poly-ε-caprolactone nanoparticles for pharmaceutical applications. J. Colloid Interface Sci. 322, 505 (2008).
51. J. Araújo, S. Nikolic, M. A. Egea, E. B. Souto, and M. L. Garcia, Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf., B 88, 150 (2011).
52. R. V. Contri, M. Kaiser, F. S. Poletto, A. R. Pohlmann, and S. S. Guterres, Simultaneous control of capsaicinoids release from polymeric nanocapsules. J. Nanosci. Nanotechnol. 11, 2398 (2011).
53. C. P. Oliveira, C. G. Venturini, B. Donida, F. S. Poletto, S. S. Guterres, and A. R. Pohlmann, An algorithm to determine the mechanism of drug distribution in lipid-core nanocapsule formulations. Soft Matter 9, 1141 (2013).
54. F. S. Poletto, E. Jäger, L. Cruz, A. R. Pohlmann, and S. S. Guterres, The effect of polymeric wall on the permeability of drug-loaded nanocapsules. Mater. Sci. Eng. C 28, 472 (2008).
55. A. Jäger, V. Stefani, S. S. Guterres, and A. R. Pohlmann, Physicochemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes. Int. J. Pharm. 338, 297 (2007).
56. H. Zahir, G. McCaughan, M. Gleeson, R. A. Nand, and A. J. McLachlan, Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br. J. Clin. Pharmacol. 57, 298 (2004).
57. D. A. Parasrampuria, M. V. Lantz, and L. Z. Benet, A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (p-Gp) function 1. Pharm. Res. 18, 39 (2001).
58. U. Hanke, K. May, V. Rozehnal, S. Nagel, W. Siegmund, and W. Weitschies, Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur. J. Pharm. Biopharm. 76, 260 (2010).
59. S. D. Tröster, U. Müller, and J. Kreuter, Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61, 85 (1990).
60. J. Kreuter, Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47, 65 (2001).
61. A. Bernardi, E. Braganhol, E. Jäger, F. Figueiró, M. I. Edelweiss, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53 (2009).
62. G. Ponchel and J. Irache, Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34, 191 (1998).
63. C. N. Grama, D. D. Ankola, and M. N. V. R. Kumar, Poly(lactide-co- glycolide) nanoparticles for peroral delivery of bioactives. Curr. Opin. Colloid Interface Sci. 16, 238 (2011).
64. N. Ide, T. Nagayasu, K. Matsumoto, T. Tagawa, K. Tanaka, T. Taguchi, Y. Sumida, and M. Nakashima, Efficacy and safety of inhaled tacrolimus in rat lung transplantation. J. Thorac. Cardiovasc. Surg. 133, 548 (2007).